Literature DB >> 10824882

Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?

G J Park1, B P Lin, M C Ngu, D B Jones, P H Katelaris.   

Abstract

BACKGROUND: The clinical usefulness of the ratio of serum aspartate aminotransferase (AST) to alanine aminotransferase (ALT) has been explored in several liver disorders. It has been suggested that in patients with chronic hepatitis C virus (HCV) infection an AST:ALT > or = 1 has 100% specificity and positive predictive value in distinguishing cirrhotic from non-cirrhotic patients. Such statistical certainty attached to a simple biochemical test merits further evaluation. The present study, therefore, assessed the AST:ALT in patients with chronic HCV infection to determine the validity of the ratio in predicting cirrhosis and to correlate the ratio with the histological grade of necroinflammatory activity and fibrosis.
METHODS: A retrospective analysis of 153 patients with chronic HCV infection was conducted. Serum biochemistry had been obtained within a mean of 4 weeks of liver biopsy. The histology was scored in terms of activity and fibrosis as described by Scheuer and correlated with AST:ALT.
RESULTS: In 30 patients with cirrhosis, the mean AST:ALT (0.99 +/- 0.06) was higher than in 123 patients without cirrhosis (0.60 +/- 0.02; P < 0.001). A ratio > or = 1 had 95.9% specificity and 73.7% positive predictive value in distinguishing cirrhotic from non-cirrhotic patients, with a 46.7% sensitivity and 88.1% negative predictive value. The ratio also parallelled the Scheuer score with respect to fibrosis but not with respect to inflammation.
CONCLUSION: Although relatively insensitive, an AST:ALT > or = 1 is highly specific but not diagnostic for the presence of cirrhosis in patients with chronic HCV infection. The ratio reflects the grade of fibrosis in these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824882     DOI: 10.1046/j.1440-1746.2000.02172.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  37 in total

1.  Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases.

Authors:  Woon Geon Shin; Sang Hoon Park; Sun-Young Jun; Jae One Jung; Joon Ho Moon; Jong Pyo Kim; Kyoung Oh Kim; Cheol Hee Park; Tai Ho Hahn; Kyo-Sang Yoo; Jong Hyeok Kim; Choong Kee Park
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

2.  Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors:  Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-06-15

3.  Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C.

Authors:  Agostino Colli; Alice Colucci; Silvia Paggi; Mirella Fraquelli; Sara Massironi; Marco Andreoletti; Vittorio Michela; Dario Conte
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 4.  Liver function tests and their interpretation.

Authors:  B R Thapa; Anuj Walia
Journal:  Indian J Pediatr       Date:  2007-07       Impact factor: 1.967

5.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

6.  Non-invasive diagnosis of liver fibrosis.

Authors:  Hiroyasu Morikawa; Norifumi Kawada
Journal:  Clin J Gastroenterol       Date:  2011-07-31

Review 7.  Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis.

Authors:  Vasiliy Ivanovich Reshetnyak
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

8.  Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.

Authors:  Paul Feuerstadt; Simon J Hong; Lawrence J Brandt
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

9.  Non-invasive assessment of liver fibrosis in chronic hepatitis C.

Authors:  Laurent Castera
Journal:  Hepatol Int       Date:  2011-01-20       Impact factor: 6.047

10.  Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

Authors:  Robert P Myers; Mercedes De Torres; Françoise Imbert-Bismut; Vlad Ratziu; Frédéric Charlotte; Thierry Poynard
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.